CompletedNCT00238485
52-week licarbazepine extension after a 6-week mania study
About this title
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
Read the official source — NCT00238485This study evaluated the safety of Licarbazepine for people with bipolarity.
Medication studyAges 18–70
Understand this study
What did researchers investigate?
This study evaluated the safety of Licarbazepine for people with bipolarity.
Who was this study for?
Listed age limits: 18 years to 70 years.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 251
- Sponsor
- Novartis
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00238485
- Official title
Show the full official title
A 52-week, Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750 - 2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety of Licarbazepine for people with bipolarity.
Who is behind this study?
The study sponsor is Novartis.
Did this study involve medication?
Yes. The study involved medication, including Licarbazepine.
Who was this study for?
Listed age limits: 18 years to 70 years.
Want to explore more studies?
Explore studiesRelated studies
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
Asenapine added to lithium or valproate for mania in bipolar I